Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a significant stock price drop triggered by a new federal kidney care strategy announced by the U.S. Department of Health and Human Services. The plan aims to increase competition in the dialysis market and shift incentives toward early preventive care, which negatively impacted DaVita's stock, falling over 6% on October 20, 2026. This investigation could lead to legal action if misconduct is found, affecting investors and the company's future operations.
As of Nov 04, 2026 06:11 WIB, DaVita Inc (DVA) trades on Pluang at USD 180.81, down 2.65% in the past day. The stock shows a market cap of $11.68 billion and an enterprise value of $24.51 billion, with a typical hold time of 117 days among investors. Current order activity on Pluang leans toward selling, with 68% of orders as Sell and 32% as Buy.
